News & Events
Since 1997, the Tumor Immunotherapy Program has been at the forefront of efforts to beat cancer through the development of new vaccines.
Led by Howard L. Kaufman, MD, Chief, Division of Surgical Oncology, the program conducts laboratory research and offers vaccines to patients with melanoma, colon cancer, kidney cancer, and other types of cancer including breast cancer.
The Interleukin-2 Unit of the NewYork-Presbyterian Tumor Immunotherapy Program at Columbia University Medical Center uses interleukin-2, or IL-2, to treat patients who have malignant melanoma and advanced kidney cancer.
IL-2 represents one of the best treatment options for patients with advanced melanoma and kidney cancer.
Advances in Melanoma CME
| Date | September 9, 2006 |
|---|
| Description | Symposium to discuss emerging therapeutic strategies, including the current status of both adjuvant and neoadjuvant treatments with vaccines and biochemotherapy regimens for early-stage disease. In addition, the clinical utility of biologic therapies and the role of novel targeted agents in the clinical management of advanced malignant melanoma will be assessed. |
|---|
| Contact | For more information and registration, pleas visit www.Melanoma.CancerConferences.com. |
|---|
| Brochure | download pdf brochure |
|---|
We are pleased to introduce the New York Melanoma Consortium Discussion Board, a place where patients can discuss experiences, share information, and get support from others.
The Melanoma Book: A Complete Guide to Prevention and Treatment,
Including the Early-Detection Self-Exam Body Map
Everything You Need to Know to Prevent—and Survive—a Diagnosis of Melanoma.
The fastest rising form of cancer worldwide, melanoma can strike at any age. Although rates of cure are higher than they used to be, experts often disagree about the best course of treatment and patients face a bewildering array of possibilities—often with precious little time to choose. Drawing on his years as one of the nation's foremost researchers and specialists in the field of melanoma treatment, Dr. Howard L. Kaufman shares his easy-to-follow, whole-life plan for detecting melanoma early, making informed decisions after a diagnosis, and taking an active role in treatment.
To contact the Tumor Vaccine Program about the TroVax-IL-2 trial, physicians may contact Gail DeRaffele, RN at 212.342.0232 or gd2023@columbia.edu.
Tumor Immunology Journal Club
| Location | P&S 17-412, conference room |
|---|
| Day | Wednesdays, weekly |
|---|
| Time | 12:30–1:30pm |
|---|
For schedules or if you would like to join our Journal Club, please
call 212.342.6042.
Lab Meeting
| Location | P&S 17-412, conference room |
|---|
| Day | Mondays, weekly |
|---|
| Time | 3:00–5:00pm |
|---|
Melanoma Tumor Board
| Location | IP-Garden Center Conference Room |
|---|
| Day | Tuesdays, weekly |
|---|
| Time | 12:00–1:00pm |
|---|
To submit a case, please contact Gail deRaffele, RN at 212.342.0232
or gd2023@columbia.edu.
IL-2 SUPPORT GROUP
| Location | MHB, 5-411 Conference Room |
|---|
| Day | Tuesdays, monthly |
|---|
| Time | 12:30–2:00pm |
|---|
Location & Date to be determined.
For more information about the New York City Melanoma Consortium, please contact Gail deRaffele, RN at 212.342.0232 or gd2023@columbia.edu.
|
